A specialty
vaccine company
Valneva at a glance
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
2023 Highlights
Valneva achieved several key milestones in 2023, including the U.S. approval of the world’s first chikungunya vaccine.
Our vaccine pipeline
At Valneva, we take a specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solution.
Our strategy
Valneva aims to become a globally recognized vaccine company focused on vaccines that make a difference.
Our Global Operations
To develop, manufacture, and commercialize vaccines globally, Valneva maintains sites and affiliates in six countries.
Our Commercial Business
Valneva commercializes its own travel vaccines against Japanese encephalitis and cholera, as well as third party-products, in key markets. The Company has just launched its single-shot chikungunya vaccine in the U.S.